An application, Ekiva-MS, has been released with the intention of transforming the lives of individuals living with multiple sclerosis, providing them with a deeper comprehension of the disease and enhanced care. In collaboration with Dawn Health, a Danish health-focused software developer, Novartis joined forces to create this innovative software platform, designed to effectively aid individuals in managing chronic illnesses.
The first product to result from the partnership between Dawn Health and Novartis is called Ekiva-MS. The product was launched in just 6 months because of strong patient co-creation and quick technological development. It serves as an example of how quickly and effectively digital health may improve patient care. The success of this partnership stemmed from the invaluable insights of actual multiple sclerosis patients, coupled with the combined expertise of both companies: Novartis’ vast knowledge in disease research and digital health, and Dawn’s proficiency in digital therapeutics and software-as-a-medical-device tools.
Enhancing MS Management with Ekiva-MS
- Ekiva-MS gathers diverse health and behavioral data from users to understand the impact of multiple sclerosis on their daily lives.
- The app empowers users to collaborate closely with healthcare providers to devise personalized treatment plans based on the gathered knowledge.
- Various techniques, including manual symptom tracking and smartphone sensor data, are used by Ekiva-MS to collect information.
- Seamless integration with existing health-tracking tools like dreaMS enables doctor-tailored assessments of essential digital biomarkers, such as movement, balance, skill, and vision.
As users continue to provide information, Ekiva-MS offers valuable tips for symptom management. Moreover, it consolidates all the gathered data into a comprehensive report that users can readily share with their healthcare providers, affording them the opportunity to highlight specific instances or information they wish to discuss during future check-ups.
The initial release of the app is in Germany, where multiple sclerosis patients can freely download it onto their smartphones. Novartis has consistently demonstrated its commitment to digital health, engaging in collaborations with tech developers to create digital therapeutics for various health conditions, including lazy eye, as well as software platforms aimed at enhancing heart disease management.
One notable recent health tech partnership involved Anumana, where Novartis explored AI-based algorithms to detect dangerous heart disease cases at an early stage, even before symptoms manifest. This unwavering dedication underscores the company’s mission to leverage technology for advancing healthcare and ultimately improving patient outcomes.
